心血管管理系统对高风险老年人三重风险因素控制的有效性:随机对照试验协议
Yan Wang1, Lei Su2, Jingyi Xiao1
1Centre of Health Management, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
JMIR research protocols
|December 9, 2025
概括
这项随机试验将评估 CardioCare 系统在高风险成年人中管理心血管疾病风险因素. 它旨在改善三重风险因素控制,提高患者的治疗结果和医疗保健策略.
科学领域:
- 心血管疾病 (CVD) 研究
- 数字健康干预措施 数字健康干预措施
- 公共卫生管理公共卫生管理
背景情况:
- 心血管疾病 (CVD) 是中国的一大健康问题.
- 目前的公共卫生计划提供了对心血管疾病风险因素的有限的查后管理.
- 卡迪奥凯尔系统为心血管风险管理提供了一个数字解决方案.
研究的目的:
- 评估 CardioCare 系统在高风险成年人中实现三重风险因素控制 (血压,脂质,血糖) 的有效性.
- 评估二次结果,包括心血管疾病风险,临床参数,药物坚持,生活方式变化和系统可用性.
- 为了确定 CardioCare 干预的成本效益.
主要方法:
- 一个单中心,优越性随机对照试验与1:1分配.
- 将招募300名年龄≥50岁,患心血管疾病10年风险高于10%的成年人.
- 干预组接受了 CardioCare 系统 (风险分层,个性化信息,心脏病专家监督);对照组接受了通常的护理12个月.
主要成果:
- 主要结局:12个月后实现三重风险因素控制的比例.
- 二次结果:临床,行为,可用性和经济指标的变化.
- 分析将遵循治疗意图原则,对缺少的数据进行多次归算.
结论:
- 该试验将提供关于 CardioCare 系统临床和成本效益的证据.
- 结果可能支持在健康检查中心扩大干预.
- 结果可以为慢性疾病管理的国家战略提供信息.
相关概念视频
01:26Atherosclerosis III: Management
296
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
296
01:21Rheumatic Heart Disease III: Medical Management
267
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
267
01:26Coronary Artery Disease IV: Preventive Measures
575
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
575
01:30Heart Failure V: Medical Management
200
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
200
01:27Peripheral Artery Disease III: Interprofessional Care
226
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
226
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
578
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
578